~~<i id='AD680714B8'><strike id='AD680714B8'><tt id='AD680714B8'><pre id='AD680714B8'></pre></tt></strike></i>~~

Home» Wikipedia» explore

explore

author：comprehensive 2025-09-30 20:48:47 Page View：4752

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BIO selects John Crowley as new CEO
Next article： Heart attack and stroke risk calculators need revising

explore

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

HugraduatingfromJohnsHopkinsandbeinginductedintotheDeltaOmegaPublicHealthHonorSocietyin2017.Courtesy

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Will the market for weight loss drugs really reach $100 billion?

DamianGardeofSTAT,left,talkedwithLiisaBaykoofEvercoreISIandJaredHolzofMizuhoabouttheGLP-1weightlossm